Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders
Background and purpose Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [18F]fluoro‐deoxy‐glucose positron emission tomography Statistical Par...
Gespeichert in:
| Veröffentlicht in: | European journal of neurology 2017-05, Vol.24 (5), p.687-e26 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e26 |
|---|---|
| container_issue | 5 |
| container_start_page | 687 |
| container_title | European journal of neurology |
| container_volume | 24 |
| creator | Caminiti, S. P. Alongi, P. Majno, L. Volontè, M. A. Cerami, C. Gianolli, L. Comi, G. Perani, D. |
| description | Background and purpose
Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [18F]fluoro‐deoxy‐glucose positron emission tomography Statistical Parametric Mapping (SPM) optimized procedure in supporting the early and differential diagnosis of APD.
Methods
Seventy patients with possible APD were retrospectively included from a large clinical cohort. The included patients underwent [18F]fluoro‐deoxy‐glucose positron emission tomography within 3 months of the first clinical assessment and a diagnostic follow‐up. An optimized SPM voxel‐wise procedure was used to produce t‐maps of brain hypometabolism in single subjects, which were classified by experts blinded to any clinical information. We compared the accuracy of both the first clinical diagnosis and the SPM t‐map classifications with the diagnosis at follow‐up as the reference standard.
Results
At first diagnosis, 60% of patients were classified as possible APD (progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy) and about 40% as APD with uncertain diagnosis, providing 52% sensitivity, 97% specificity and 86% accuracy with respect to the reference standard. SPM t‐map classification showed 98% sensitivity, 99% specificity and 99% accuracy, and a significant agreement with the diagnosis at follow‐up (P < 0.001).
Conclusions
The SPM t‐map classification at entry predicted the second diagnosis at follow‐up. This indicates its significantly superior role for an early identification of APD subtypes, particularly in cases of uncertain diagnosis. The use of a metabolic biomarker at entry in the instrumental work‐up of APD may shorten the diagnostic time, producing benefits for treatment options and support to the patients. |
| doi_str_mv | 10.1111/ene.13269 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891850682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321727611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3869-f1c81119123ac0e8ce95e69c75c0dc16b7c5ef11c4f095721907fa35b2229df33</originalsourceid><addsrcrecordid>eNqNkU9u1TAQxiNERUthwQWQJTZlkdbj_LOXqHoFpKplASuEIj9n_OrixMFO2oYVR-AwnIiTdMorLJCQ8MJjj3_zyTNflj0Dfgi0jnDAQyhErR5ke1DWMoeigId0LirIK-Cwmz1O6ZJzLhrBH2W7QoqyhEbuZT9WV9rPenJhYMEyTfs4ud59xY59BHnyyfo5xPDz2_cOw81CceNnExKyMSQ3RSrD3qV0Vz-FPmyiHi8WdhVu0BN87YjscboIHT0z1NEvLM3jGOLEOmctRhwmpz1d9GYgycTcwPS0jM5Q9p2On92QwuDoZ51LIXYY05Nsx2qf8Ol93M8-nKzeH7_JT89fvz1-dZqbQtYqt2AkjUeBKLThKA2qCmtlmsrwzkC9bkyFFsCUlquqEaB4Y3VRrYUQqrNFsZ8dbHXHGL7MmKaWWjXovR4wzKkFqUBWvJbiP9BGSAmq5IS--Au9DHMcqBGipKxqpRog6uWWMjGkFNG2Y3S9jksLvL1zvSXX21-uE_v8XnFe99j9IX_bTMDRFrh2Hpd_K7Wrs9VW8hYtLr2J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1888569971</pqid></control><display><type>article</type><title>Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Caminiti, S. P. ; Alongi, P. ; Majno, L. ; Volontè, M. A. ; Cerami, C. ; Gianolli, L. ; Comi, G. ; Perani, D.</creator><creatorcontrib>Caminiti, S. P. ; Alongi, P. ; Majno, L. ; Volontè, M. A. ; Cerami, C. ; Gianolli, L. ; Comi, G. ; Perani, D.</creatorcontrib><description>Background and purpose
Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [18F]fluoro‐deoxy‐glucose positron emission tomography Statistical Parametric Mapping (SPM) optimized procedure in supporting the early and differential diagnosis of APD.
Methods
Seventy patients with possible APD were retrospectively included from a large clinical cohort. The included patients underwent [18F]fluoro‐deoxy‐glucose positron emission tomography within 3 months of the first clinical assessment and a diagnostic follow‐up. An optimized SPM voxel‐wise procedure was used to produce t‐maps of brain hypometabolism in single subjects, which were classified by experts blinded to any clinical information. We compared the accuracy of both the first clinical diagnosis and the SPM t‐map classifications with the diagnosis at follow‐up as the reference standard.
Results
At first diagnosis, 60% of patients were classified as possible APD (progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy) and about 40% as APD with uncertain diagnosis, providing 52% sensitivity, 97% specificity and 86% accuracy with respect to the reference standard. SPM t‐map classification showed 98% sensitivity, 99% specificity and 99% accuracy, and a significant agreement with the diagnosis at follow‐up (P < 0.001).
Conclusions
The SPM t‐map classification at entry predicted the second diagnosis at follow‐up. This indicates its significantly superior role for an early identification of APD subtypes, particularly in cases of uncertain diagnosis. The use of a metabolic biomarker at entry in the instrumental work‐up of APD may shorten the diagnostic time, producing benefits for treatment options and support to the patients.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.13269</identifier><identifier>PMID: 28244178</identifier><identifier>CODEN: EJNEFL</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Accuracy ; Aged ; Aged, 80 and over ; Basal Ganglia Diseases - diagnostic imaging ; Basal Ganglia Diseases - metabolism ; biomarkers ; corticobasal degeneration ; dementia with Lewy bodies ; Diagnosis, Differential ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Glucose ; Humans ; hypometabolism ; Male ; Middle Aged ; multiple system atrophy ; Neurodegenerative Diseases - diagnostic imaging ; Neurodegenerative Diseases - metabolism ; Parkinsonian Disorders - diagnostic imaging ; Parkinsonian Disorders - metabolism ; Positron-Emission Tomography - methods ; progressive supranuclear palsy ; Radiopharmaceuticals ; Retrospective Studies ; Sensitivity and Specificity ; single subject ; Statistical Parametric Mapping ; Tomography</subject><ispartof>European journal of neurology, 2017-05, Vol.24 (5), p.687-e26</ispartof><rights>2017 EAN</rights><rights>2017 EAN.</rights><rights>2017 European Federation of Neurological Societies</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3869-f1c81119123ac0e8ce95e69c75c0dc16b7c5ef11c4f095721907fa35b2229df33</citedby><cites>FETCH-LOGICAL-c3869-f1c81119123ac0e8ce95e69c75c0dc16b7c5ef11c4f095721907fa35b2229df33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.13269$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.13269$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28244178$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caminiti, S. P.</creatorcontrib><creatorcontrib>Alongi, P.</creatorcontrib><creatorcontrib>Majno, L.</creatorcontrib><creatorcontrib>Volontè, M. A.</creatorcontrib><creatorcontrib>Cerami, C.</creatorcontrib><creatorcontrib>Gianolli, L.</creatorcontrib><creatorcontrib>Comi, G.</creatorcontrib><creatorcontrib>Perani, D.</creatorcontrib><title>Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background and purpose
Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [18F]fluoro‐deoxy‐glucose positron emission tomography Statistical Parametric Mapping (SPM) optimized procedure in supporting the early and differential diagnosis of APD.
Methods
Seventy patients with possible APD were retrospectively included from a large clinical cohort. The included patients underwent [18F]fluoro‐deoxy‐glucose positron emission tomography within 3 months of the first clinical assessment and a diagnostic follow‐up. An optimized SPM voxel‐wise procedure was used to produce t‐maps of brain hypometabolism in single subjects, which were classified by experts blinded to any clinical information. We compared the accuracy of both the first clinical diagnosis and the SPM t‐map classifications with the diagnosis at follow‐up as the reference standard.
Results
At first diagnosis, 60% of patients were classified as possible APD (progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy) and about 40% as APD with uncertain diagnosis, providing 52% sensitivity, 97% specificity and 86% accuracy with respect to the reference standard. SPM t‐map classification showed 98% sensitivity, 99% specificity and 99% accuracy, and a significant agreement with the diagnosis at follow‐up (P < 0.001).
Conclusions
The SPM t‐map classification at entry predicted the second diagnosis at follow‐up. This indicates its significantly superior role for an early identification of APD subtypes, particularly in cases of uncertain diagnosis. The use of a metabolic biomarker at entry in the instrumental work‐up of APD may shorten the diagnostic time, producing benefits for treatment options and support to the patients.</description><subject>Accuracy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Basal Ganglia Diseases - diagnostic imaging</subject><subject>Basal Ganglia Diseases - metabolism</subject><subject>biomarkers</subject><subject>corticobasal degeneration</subject><subject>dementia with Lewy bodies</subject><subject>Diagnosis, Differential</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Follow-Up Studies</subject><subject>Glucose</subject><subject>Humans</subject><subject>hypometabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multiple system atrophy</subject><subject>Neurodegenerative Diseases - diagnostic imaging</subject><subject>Neurodegenerative Diseases - metabolism</subject><subject>Parkinsonian Disorders - diagnostic imaging</subject><subject>Parkinsonian Disorders - metabolism</subject><subject>Positron-Emission Tomography - methods</subject><subject>progressive supranuclear palsy</subject><subject>Radiopharmaceuticals</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>single subject</subject><subject>Statistical Parametric Mapping</subject><subject>Tomography</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU9u1TAQxiNERUthwQWQJTZlkdbj_LOXqHoFpKplASuEIj9n_OrixMFO2oYVR-AwnIiTdMorLJCQ8MJjj3_zyTNflj0Dfgi0jnDAQyhErR5ke1DWMoeigId0LirIK-Cwmz1O6ZJzLhrBH2W7QoqyhEbuZT9WV9rPenJhYMEyTfs4ud59xY59BHnyyfo5xPDz2_cOw81CceNnExKyMSQ3RSrD3qV0Vz-FPmyiHi8WdhVu0BN87YjscboIHT0z1NEvLM3jGOLEOmctRhwmpz1d9GYgycTcwPS0jM5Q9p2On92QwuDoZ51LIXYY05Nsx2qf8Ol93M8-nKzeH7_JT89fvz1-dZqbQtYqt2AkjUeBKLThKA2qCmtlmsrwzkC9bkyFFsCUlquqEaB4Y3VRrYUQqrNFsZ8dbHXHGL7MmKaWWjXovR4wzKkFqUBWvJbiP9BGSAmq5IS--Au9DHMcqBGipKxqpRog6uWWMjGkFNG2Y3S9jksLvL1zvSXX21-uE_v8XnFe99j9IX_bTMDRFrh2Hpd_K7Wrs9VW8hYtLr2J</recordid><startdate>201705</startdate><enddate>201705</enddate><creator>Caminiti, S. P.</creator><creator>Alongi, P.</creator><creator>Majno, L.</creator><creator>Volontè, M. A.</creator><creator>Cerami, C.</creator><creator>Gianolli, L.</creator><creator>Comi, G.</creator><creator>Perani, D.</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201705</creationdate><title>Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders</title><author>Caminiti, S. P. ; Alongi, P. ; Majno, L. ; Volontè, M. A. ; Cerami, C. ; Gianolli, L. ; Comi, G. ; Perani, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3869-f1c81119123ac0e8ce95e69c75c0dc16b7c5ef11c4f095721907fa35b2229df33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Accuracy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Basal Ganglia Diseases - diagnostic imaging</topic><topic>Basal Ganglia Diseases - metabolism</topic><topic>biomarkers</topic><topic>corticobasal degeneration</topic><topic>dementia with Lewy bodies</topic><topic>Diagnosis, Differential</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Follow-Up Studies</topic><topic>Glucose</topic><topic>Humans</topic><topic>hypometabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multiple system atrophy</topic><topic>Neurodegenerative Diseases - diagnostic imaging</topic><topic>Neurodegenerative Diseases - metabolism</topic><topic>Parkinsonian Disorders - diagnostic imaging</topic><topic>Parkinsonian Disorders - metabolism</topic><topic>Positron-Emission Tomography - methods</topic><topic>progressive supranuclear palsy</topic><topic>Radiopharmaceuticals</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>single subject</topic><topic>Statistical Parametric Mapping</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caminiti, S. P.</creatorcontrib><creatorcontrib>Alongi, P.</creatorcontrib><creatorcontrib>Majno, L.</creatorcontrib><creatorcontrib>Volontè, M. A.</creatorcontrib><creatorcontrib>Cerami, C.</creatorcontrib><creatorcontrib>Gianolli, L.</creatorcontrib><creatorcontrib>Comi, G.</creatorcontrib><creatorcontrib>Perani, D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caminiti, S. P.</au><au>Alongi, P.</au><au>Majno, L.</au><au>Volontè, M. A.</au><au>Cerami, C.</au><au>Gianolli, L.</au><au>Comi, G.</au><au>Perani, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2017-05</date><risdate>2017</risdate><volume>24</volume><issue>5</issue><spage>687</spage><epage>e26</epage><pages>687-e26</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><coden>EJNEFL</coden><abstract>Background and purpose
Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [18F]fluoro‐deoxy‐glucose positron emission tomography Statistical Parametric Mapping (SPM) optimized procedure in supporting the early and differential diagnosis of APD.
Methods
Seventy patients with possible APD were retrospectively included from a large clinical cohort. The included patients underwent [18F]fluoro‐deoxy‐glucose positron emission tomography within 3 months of the first clinical assessment and a diagnostic follow‐up. An optimized SPM voxel‐wise procedure was used to produce t‐maps of brain hypometabolism in single subjects, which were classified by experts blinded to any clinical information. We compared the accuracy of both the first clinical diagnosis and the SPM t‐map classifications with the diagnosis at follow‐up as the reference standard.
Results
At first diagnosis, 60% of patients were classified as possible APD (progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy) and about 40% as APD with uncertain diagnosis, providing 52% sensitivity, 97% specificity and 86% accuracy with respect to the reference standard. SPM t‐map classification showed 98% sensitivity, 99% specificity and 99% accuracy, and a significant agreement with the diagnosis at follow‐up (P < 0.001).
Conclusions
The SPM t‐map classification at entry predicted the second diagnosis at follow‐up. This indicates its significantly superior role for an early identification of APD subtypes, particularly in cases of uncertain diagnosis. The use of a metabolic biomarker at entry in the instrumental work‐up of APD may shorten the diagnostic time, producing benefits for treatment options and support to the patients.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>28244178</pmid><doi>10.1111/ene.13269</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1351-5101 |
| ispartof | European journal of neurology, 2017-05, Vol.24 (5), p.687-e26 |
| issn | 1351-5101 1468-1331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891850682 |
| source | MEDLINE; Wiley Journals |
| subjects | Accuracy Aged Aged, 80 and over Basal Ganglia Diseases - diagnostic imaging Basal Ganglia Diseases - metabolism biomarkers corticobasal degeneration dementia with Lewy bodies Diagnosis, Differential Female Fluorodeoxyglucose F18 Follow-Up Studies Glucose Humans hypometabolism Male Middle Aged multiple system atrophy Neurodegenerative Diseases - diagnostic imaging Neurodegenerative Diseases - metabolism Parkinsonian Disorders - diagnostic imaging Parkinsonian Disorders - metabolism Positron-Emission Tomography - methods progressive supranuclear palsy Radiopharmaceuticals Retrospective Studies Sensitivity and Specificity single subject Statistical Parametric Mapping Tomography |
| title | Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T03%3A07%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20an%20optimized%20%5B18F%5Dfluoro%E2%80%90deoxy%E2%80%90glucose%20positron%20emission%20tomography%20voxel%E2%80%90wise%20method%20to%20early%20support%20differential%20diagnosis%20in%20atypical%20Parkinsonian%20disorders&rft.jtitle=European%20journal%20of%20neurology&rft.au=Caminiti,%20S.%20P.&rft.date=2017-05&rft.volume=24&rft.issue=5&rft.spage=687&rft.epage=e26&rft.pages=687-e26&rft.issn=1351-5101&rft.eissn=1468-1331&rft.coden=EJNEFL&rft_id=info:doi/10.1111/ene.13269&rft_dat=%3Cproquest_cross%3E4321727611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1888569971&rft_id=info:pmid/28244178&rfr_iscdi=true |